Tasly Pharmaceutical Group Co., Ltd
SHSE:600535 Stock Report
Tasly Pharmaceutical Group Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Jing Su
Chief executive officer
CN¥2.7m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?
Jul 22Estimating The Intrinsic Value Of Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)
Jun 13The Market Doesn't Like What It Sees From Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Earnings Yet
May 13Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively
Apr 26Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?
Mar 15
CEO
Mr. Jing Su is General Manager and Director of Tasly Pharmaceutical Group Co., Ltd.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
